Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.

Literature DB >> 16188169

Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.

Abstract

Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that promotes glucose homeostasis through the regulation of insulin and glucagon secretion, gastric emptying, and food intake. This spectrum of effects makes GLP-1 an attractive candidate for drug development. However, because GLP-1 is a small peptide with rapid metabolism in the circulation, its usefulness to treat patients is limited. However, GLP-1 mimetics that are resistant to degradation have been developed and are effective in lowering blood glucose in diabetic patients. A second strategy for harnessing GLP-1 therapeutically is to inhibit the metabolism of endogenous GLP-1; several orally available compounds are in clinical trials. These two new classes of drugs both enhance GLP-1 signaling but differ in several key characteristics that may lead to distinct roles in the treatment of diabetic patients.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 16188169 DOI： 10.1007/s11892-005-0092-2

Source DB: PubMed Journal: Curr Diab Rep ISSN： 1534-4827 Impact factor: 4.810

60 in total

1. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.

Authors: Torsten P Vahl; Breay W Paty; Bradley D Fuller; Ronald L Prigeon; David A D'Alessio
Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958

2. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.

Authors: Josephine M Egan; Astrid R Clocquet; Dariush Elahi
Journal: J Clin Endocrinol Metab Date: 2002-03 Impact factor: 5.958

3. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Authors: L A Scrocchi; T J Brown; N MaClusky; P L Brubaker; A B Auerbach; A L Joyner; D J Drucker
Journal: Nat Med Date: 1996-11 Impact factor: 53.440

4. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Authors: Mark S Fineman; Thomas A Bicsak; Larry Z Shen; Kristin Taylor; Eling Gaines; Amanda Varns; Dennis Kim; Alain D Baron
Journal: Diabetes Care Date: 2003-08 Impact factor: 19.112

5. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.

Authors: Mark S Fineman; Larry Z Shen; Kristin Taylor; Dennis D Kim; Alain D Baron
Journal: Diabetes Metab Res Rev Date: 2004 Sep-Oct Impact factor: 4.876

6. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.

Authors: Atsushi Nakagawa; Hanae Satake; Hajime Nakabayashi; Makoto Nishizawa; Keisuke Furuya; Shigeru Nakano; Toshikazu Kigoshi; Kohzo Nakayama; Kenzo Uchida
Journal: Auton Neurosci Date: 2004-01-30 Impact factor: 3.145

7. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors: B Thorens
Journal: Proc Natl Acad Sci U S A Date: 1992-09-15 Impact factor: 11.205

8. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.

Authors: A Hvidberg; M T Nielsen; J Hilsted; C Orskov; J J Holst
Journal: Metabolism Date: 1994-01 Impact factor: 8.694

9. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Authors: T J Kieffer; C H McIntosh; R A Pederson
Journal: Endocrinology Date: 1995-08 Impact factor: 4.736

Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.

1. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.

2. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.

3. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

4. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

5. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.

6. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.

7. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

8. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.

9. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

10. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin.

Review 1. Central control of body weight and appetite.

Review 2. Hypothalamic control of energy and glucose metabolism.

Review 3. The control of food intake: behavioral versus molecular perspectives.

4. Meal-anticipatory glucagon-like peptide-1 secretion in rats.